Type 2 diabetes
Conditions
Interventions
None listed
Sponsors
Sanofi K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult Japanese patients with T2DM who met all of the following inclusion criteria will be enrolled into the study. (1)Initiated iGlarLixi at least 6 months before data collection regardless of treatment continuation or discontinuation (2)Have at least one HbA1c value recorded within 3 months prior to initiation of iGlarLixi (3)Have body weight data recorded within 6 months prior to iGlarLixi initiation (4)Have at least one HbA1c value recorded within 6 months after the initiation of iGlarLixi (5)Signed informed consent
Exclusion criteria
Exclusion criteria: Patients who met any of the following exclusion criteria will be excluded from the study. (1)Have a diagnosis of type 1 diabetes (2)Age <18 years old at initiation of iGlarLixi (3)Pregnant during the observation period (4)Previously participated in any iGlarLixi clinical trials or enrolled in any clinical trial related to diabetes during the observation period (5)Previously treated with IDegLira within 3 months prior to initiation of iGlarLixi (6)Off label use of iGlarLixi (e.g., Administration other than before breakfast, administering twice a day, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HbA1c from baseline to 6 months after the initiation of iGlarLixi | — |
Countries
Japan
Contacts
Public ContactPublic contact SPARTA Japan public contact
Sanofi K,K. General medicine medical
Outcome results
None listed